Crosswinds Holdings Inc. Reports Q3 2017 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
366
Crosswinds Holdings Inc. Reports Q3 2017 Financial Results

TORONTO, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Crosswinds Holdings Inc. (“Crosswinds” or the “Company”) (TSX: CWI ) today announced its financial results as at and for the three and nine months ended September 30, 2017.

Business Highlights 

  • The Company’s recorded a loss for the third quarter primarily driven by negative performance on its investment in Monarch Delaware Holdings LLC and its subsidiaries (“Monarch”) as a result of Hurricane Irma which made landfall in Florida in September 2017 combined with weak underwriting performance.
  • Crosswinds is in discussions regarding a sale of its joint venture investment in Monarch to its joint venture partner.  There can be no assurance such discussions will result in a transaction and any such transaction would be conditioned on definitive documentation and regulatory approval.
  • Crosswinds Re did not participate in 2017 Florida reinsurance renewals after determining that rates were insufficient for Crosswinds Re’s rate of return targets.
  • The Company implemented a normal course issuer bid in the third quarter as the Company believes this is currently the best use of its available capital.

Q3 2017 Financial Highlights

For the three months ended September 30, 2017, the Company reported: 

  • Net loss of $(2,593,144) or $(0.28) per common share (“Share”) compared to net loss of $(282,230) or $(0.05) per Share for the three months ended September 30, 2016. Until such time as (i) Monarch’s performance improves or a strategic change is made to this investment; and/or (ii) Crosswinds Re becomes active and profitable, the Company expects its revenues to be constrained;  
  • Share of loss from Monarch of $(2.4 million) compared to share of income of $0.1 million for the three months ended September 30, 2016;
  • Shareholders’ equity attributable to Crosswinds’ shareholders (or net book value 1 ) of $20.2 million or $2.19 per Share1 compared to $20.2 million or $3.81 per Share 1 at December 31, 2016; and
  • $0.7 million of the decrease in net book value 1 during the quarter represents unrealized foreign exchange loss on translating the USD denominated investment in Monarch into Canadian dollars for financial statement purposes in an environment where the Canadian dollar has strengthened.  The Monarch investment is subject to significant foreign currency fluctuations which are unrealized but can distort the investment performance. 

For the nine months ended September 30, 2017, the Company reported:

  • Net loss of $(3,961,054) or $(0.47) per Share compared to net loss of $(994,502) or $(0.17) per Share for the nine months ended September 30, 2016; and
  • Share of loss from Monarch of $(2.9) million compared to income of $0.3 million for the nine months ended September 30, 2016.

[1]  Net book value per share is a non-IFRS financial measure and is calculated as total shareholders’ equity under International Financial Reporting Standards (IFRS) divided by the number of common shares outstanding as at the period end.  See the cautionary statement regarding use of Non-IFRS financial measures at the end of this release.

Statement of Operations Highlights

     
  Three months ended Sept. 30 Nine months ended Sept. 30
In CAD thousands, except per Share amounts  2017 2016 2017 2016
Revenue $   105  $   110 $   361 $   319
Net results of investments (2,513) 117 (3,113) 260
Expenses (533) (495) (1,627) (1,526)
Net loss $(2,941) $ (268) (4,379) (947)
Non-controlling interest’s (income) loss 348 (14) 418 (48)
Net loss attributable to the shareholders of Crosswinds $(2,593) $ (282) (3,961) (995)
Net loss per Share $ (0.28) $ (0.05) $(0.47) $(0.17)
         

For the quarter ended September 30, 2017, the Company reported:

  • Cash of $7.9 million compared to $1.6 million at December 31, 2016 reflecting the completion of a rights offering in Q1 2017 and the monetization of Salbro in Q2 2017; and
  • Carrying value of $14.3 million for Monarch compared to $18.3 million at December 31, 2016. $1.3 million of the $4.0 million decrease in the carrying value of Monarch from December 31, 2016 to the end of Q3 2017 was attributable to foreign exchange fluctuations as a result of a strengthening Canadian dollar.

 Balance Sheet Highlights  

In CAD thousands, except per Share amounts September 30, 2017 December 31, 2016 December 31, 2014
Cash $  7,899 $  1,566 $  17,118
Investments in an associate and private entity 14,255 21,322 4,038
Other assets 206 202 44
Total Assets $ 22,360 $ 23,090 $  21,200
Total Liabilities (151) (277) 552
Total Shareholders’ Equity $ 22,209 $ 22,813 $  20,648
Non-controlling interests (2,036) (2,610)  
Shareholders’ Equity attributable to the shareholders of Crosswinds $20,173 $20,203  
Number of shares outstanding (millions) 9.2 5.3 5.3
Net book value per Share attributable to the shareholders of Crosswinds $ 2.19  $ 3.81 $  3.89
       

Financial Information

For a comprehensive review of the Company’s results, shareholders are encouraged to read the Company’s condensed interim consolidated financial statements and accompanying Interim Management’s Discussion and Analysis for the period ended September 30, 2017, copies of which will be available on the Company’s website at www.crosswindsinc.com  and on SEDAR at www.sedar.com .

Crosswinds Holdings Inc.  

Crosswinds is a publicly traded private equity firm and asset manager targeting strategic and opportunistic investments in the financial services sector with a particular focus on the insurance industry. 

More information

Colin King Tel: 1-800-439-5136 info@crosswindsinc.com   www.crosswindsinc.com  

Caution Regarding Forward-Looking Information This release includes certain forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “should”, “plans” or “continue” or the negative thereof or variations thereon or similar terminology. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct.  These forward-looking statements are subject to a number of risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements. Reference should be made to the risk factors in the Company’s 2016 Annual Information Form, in the Management’s Discussion and Analysis for the year ended December 31, 2016 and in our other filings with Canadian securities regulators. Additional important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, interest rates, tax related matters, loss of personnel, reliance on key personnel, ability of the Company to generate positive future returns for investors, ability of the Company to execute its strategies from time to time; the receipt of any regulatory approvals or consents required from time to time.

Cautionary Statement Regarding the Use of Non-IFRS Financial Measures This news release makes reference to the net book value per share which is a non-IFRS financial measure both on a consolidated basis including non-controlling interests with respect to the Company’s investment in Monarch and on a non-consolidated basis attributable solely to the Company’s shareholders without non-controlling interests.  These measures are non-IFRS financial measures.  The Company calculates the net book values per Share as it believes it to be an important metric that shareholders use and frequently request and refer to because shareholders often view the Company as a holding company of investments. These non-IFRS financial measures do not have any standardized meaning prescribed by IFRS and therefore are unlikely to be comparable to a similar measure presented by other issuers.  This classification is not an IFRS measure and should not be considered either in isolation of, or as a substitute for, a measure prepared in accordance with IFRS.

Cautionary Statement Regarding the Valuation of Investments in Private Entities

For the periods prior to the sale of its investment in Salbro, fair values for this investment were determined by management using the appropriate valuation methodologies after considering the history and nature of the business, operating results and financial conditions, outlook and prospects, general economic, industry and market conditions, capital market and transaction market conditions, contractual rights relating to the investment, public market comparables, private market transaction multiples and, where applicable, other pertinent considerations. The process of valuing investments for which no active market exists is inevitably based on inherent uncertainties and the resulting values may differ from values that would have been used had an active market existed. The amounts at which the Company's investments in private entities could or are ultimately disposed of may differ from the fair value assigned and the differences could be material.         

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Coca-Cola's Recent Unusual Options Trends

Updated Category News Views 259

Analyzing Coca-Cola's Recent Options Activity Investors are showing a bearish trend toward Coca-Cola (KO), which is an important indicator for retail traders monitoring investment trends. The recent unusual options activity suggests that these investors may possess insights not yet shared with the public. Thus, individual traders should be particularly attentive to these...

Continue Reading
Sustainable Palm Oil Market Growth Driven by AI Insights

Updated Category News Views 136

Exploring the Growth of the Sustainable Palm Oil Market The sustainable palm oil market is currently on the rise, fueled by a growing demand for trans-fat-free products and innovations in eco-friendly farming practices. This growth is expected to hit around USD 2.75 billion by 2028, reflecting a solid compound annual growth rate (CAGR) of about 5.24% in the coming years....

Continue Reading
Grilling Safety Tips from Ferrellgas This Labor Day

Updated Category News Views 82

Grilling Safety Tips from Ferrellgas This Labor Day As we gear up for one of the biggest grilling holidays of the year, it's essential to keep safety in mind while savoring delicious meals with family and friends. Ferrellgas Partners, L.P. is taking this opportunity to remind customers about the significance of safe grilling practices this Labor Day. This holiday not only...

Continue Reading
Solstice Gold Secures Funding Through Successful Placement Deal

Updated Category News Views 127

Solstice Gold Completes Successful Private Placement Financing Solstice Gold Corp. (“Solstice”, “we”, “our”, or the “Company”) is thrilled to announce the successful closing of its private placement financing. This significant financial milestone comes with gross proceeds of approximately $150,000 from the issuance of 6,600,000 shares. This private...

Continue Reading
Avanos Medical Introduces Innovative CORGRIP SR System

Updated Category News Views 32

Avanos Medical Launches New CORGRIP SR Advancement to reduce dislodgement in feeding tube retention systems Avanos Medical, Inc. (NYSE: AVNS) recently announced an exciting development in its Enteral Feeding portfolio with the launch of the CORGRIP SR Nasogastric/Nasointestinal Tube Retention System. This innovative design aims to provide enhanced support and security for...

Continue Reading